This is an open-label, single-center, phase I study to assess the safety and efficacy of
convalescent plasma therapy (CPT) obtained from donors who were tested positive for
SARS-CoV-2 and fully recovered from the infection and administered to patients who are
infected with the new coronavirus and present dyspnea or a poor prognosis